| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |




From the Departments of Clinical and Anatomic Pathology,
*
the Cleveland Clinic Foundation, Cleveland, Ohio; the Department of Laboratory Medicine and Pathology,
Mayo Clinic, Rochester, Minnesota; the Department of Pathology,
University of Arizona School of Medicine, Tucson, Arizona; and the Robert E. Fechner Laboratory of Surgical Pathology,
University of Virginia School of Medicine, Charlottesville, Virginia
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
For most genes, gene copy number, message, and encoded protein measurements are concordant in that increased gene copy leads to enhanced message production and overexpression of protein. For other genes, external modulating influences on transcription and translation may be reflected in enhanced expression of mRNA and overproduction of encoded protein in the presence of two apparently normal gene copies measured by fluorescence in situ hybridization (FISH). A technique that could allow simultaneous assessment of gene copy number and production of its encoded protein could facilitate visualization of the process on a cell-by-cell level, enhancing understanding of both physiological and pathophysiological mechanisms.
A three-color fluorescence-based assay is described herein that combines conventional DNA:DNA FISH with immunohistochemical detection of the Her-2/neu cell membrane-associated oncoprotein using the bifunctional chromogen of alkaline phosphatase fast red K that has both chromogenic and fluorescent properties. In sections of formalin-fixed paraffin tissue counterstained with DAPI, the three-color fluorescence assay permitted precise quantitation of gene copy by FISH and simultaneous visualization of the encoded protein by immunohistochemistry (IHC).
Concomitant oncoprotein detection with FISH (CODFISH) represents a versatile assay for simultaneous assessment of Her-2/neu or other genomic amplification and oncoprotein expression. For Her-2/neu, the method is readily adaptable to a 2-stage algorithm whereby bright field IHC with CB11 can be followed by CODFISH to detect gene copy for clarification of ambiguous cases, significantly decreasing possible false negative or false positive interpretations now linked to important therapeutic decisions.
| Materials and Methods |
|---|
|
|
|---|
CODFISH
Unstained paraffin sections on electrostatically charged slides
were deparaffinized and rehydrated in 3 changes each of xylene,
absolute alcohol, and 95% and 80% alcohol, and then placed in 1x
phosphate-buffered saline (PBS) for 5 minutes. Cell conditioning was
achieved through the use of microwaving in citrate buffer for 15
minutes, followed by cooling of the slides in the citrate solution at
room temperature for 20 minutes. The monoclonal antibody CB11 at
manufacturers concentration was dispensed onto the sections and
allowed to incubate for 1 hour at room temperature. Sections were then
washed in 1x PBS, 2 changes of 3 minutes each, and biotinylated
anti-mouse IgG (Ventana) applied at a concentration of 15 µg/ml for
30 minutes. Two changes of 1x PBS wash at room temperature were
followed by the addition of avidin-alkaline phosphatase (Ventana) at a
concentration of 3000 µg/ml for 30 minutes. Sections were then washed
twice for 3 minutes each, in 1x PBS at room temperature, and then the
chromogen reaction product developed from the fast red K proprietary
solution (Ventana), 10 minutes at room temperature. Sections
were then washed briefly in distilled water and counter stained with
hemotoxylin for approximately 30 sections. Sections were then
dehydrated in graded alcohols.
Ten microliters of digoxigenin-labeled Her-2/neu probe in proprietary probe solution (Oncor/Ventana) were applied to the section and coverslipped, then the probe solution and target tissue were codenatured at 90o centigrade for 6 minutes followed by overnight hybridization at 37o in a humidified chamber. The coverslip was removed by soaking the slides in 2x standard saline citrate (SSC) for 5 minutes at room temperature. Washes of 0.5x SSC for 5 minutes at 72o centigrade followed. Slides were prewashed in 1x PBS containing 0.5% Tween 20 for 3 minutes at room temperature. Fluorescein-isothiocyanate-antidigoxigenin 1:50 in 1x bovine calf solution containing 0.5% bovine serum albumin was applied to the section, per slide, and allowed to incubate for 1 hour. The sections were then washed 3 times, 5 minutes each, in 1x PBS containing 0.5% Tween 20 (Sigma, St. Louis, MO). The sections were then counterstained with 20 µl DAPI in antifade solution (Oncor, Gaithersburg, MD) and mounted for FISH analysis.
The fast red K bright red chromogenic reaction product of alkaline phosphatase also displays brilliant pink-red fluorescence on excitation at 530 nm. The sections were screened by immunofluorescence without knowledge of the immunohistochemistry results, and scored in the same manner as described above.8, 9 The CODFISH Her-2/neu copy number was acquired through FISH analysis without knowledge of the DigFISH results. Signals were visualized on an Axioskop (Zeiss, Oberkochen, Germany) photomicroscope equipped with a triple bandpass filter. Images were captured through a photometric digital cooled CCD camera using a SmartCapture system (Vysis).10 Two representative fields were identified in the area preselected for probe application, and gene copy enumerated for a total of 40 nuclei, 20 in each of the two representative fields averaged.
DNA:DNA FISH (DigFISH), Site I
The same procedure sans the CB11 immunohistochemistry portion of
the CODFISH protocol was used for the DigFISH assay.
Direct Two-Color Her/2-neu/Chromosome 17 Fluorescence
Hybridization, Site II
FISH was performed using fluorescent-labeled DNA probes obtained
from Vysis, Inc. (Downers Grover, IL). Five-micron paraffin sections
were deparaffinized, dehydrated, incubated in 2x SSC at 75°C for 15
minutes, digested in pepsin solution (4 mg/ml in 0.9% NaCl, pH 1.5)
for 15 minutes at 37°C, rinsed in 2x SSC at room temperature
for 5 minutes, and air-dried. Dual-probe hybridization was performed
using a Spectrum Green-labeled probe for the centromere region of
chromosome 17 (CEP17) and a Spectrum Orange-labeled
Her-2/neu probe. The probe mixture was hybridized to an area
containing invasive carcinoma as determined on adjacent H&E-stained
section. Probes and target DNA were denatured simultaneously in an
80°C oven for 5 minutes, and hybridization performed by incubation at
37°C overnight. Posthybridization washes were performed using 1.5
mol/L urea/0.1x SSC at 45°C for 30 minutes and 2x SSC at room
temperature for 2 minutes. Nuclei were counterstained with
4,6-diamindino-2-phenylindole and antifade compound
p-phenyldiamine. The number of HER2 signals and CEP17
signals were counted in 60 nonoverlapping nuclei, and an overall mean
HER2/CEP17 ratio was calculated. Lesions with ratios
2.0 were
defined as having HER2 amplification. Site I used the CEP17 probe in
combination with the DigFISH method described. All other procedural
steps were identical for both Sites I and II.
RNA:RNA in Situ Hybridization
The formalin-fixed, paraffin-embedded breast biopsy blocks were
serially sectioned at 4 to 5 µm, and the sections were mounted on
3-aminopropyltriethoxysilane-coated slides. These sections served as
the substrate for in situ hybridization. A final serial
section was stained with H&E to verify preservation of the morphology.
Her2/neu in Situ Hybridization, Site III
In situ hybridization for Her-2/neu mRNA was
carried out using well-characterized methods.11, 12, 13
The
Her-2/neu DNA construct, pHER2436-1 (originally in pUC12),
was obtained from the American Type Culture Collection (Manassas,
VA; stock number 59297). The 1.45-kb construct was recloned into
pCDNA1, which was grown up in bulk, and template plasmids were
prepared by cesium banding. Templates for riboprobe transcription were
prepared by restriction digestion of the DNA with HindIII
for antisense transcription using SP6 polymerase and XbaI
for T7 directed sense orientation probes. In vitro
transcription to generate 3H-labeled riboprobes
was carried out in the presence of 3H-UTP and
3H-CTP (approximately 30 or 60 Ci/mmol/L,
respectively), yielding probes with a specific activity of 1.1 x
108 dpm/µg. The in situ
hybridization mixture contained 50% formamide, 0.3 mol/L NaCl, 20
mmol/L Tris-Cl, 1 mmol/L EDTA, pH 8.0, 1x Denhardts solution, 500
ng/ml yeast tRNA, and 10% dextran sulfate. Hybridization was carried
out at
Tm -25°C = 45°C. The final probe
concentrations were adjusted to just fully saturate the target messages
(0.2 µg/ml/kb complexity). Following hybridization, the
specimens were washed at high stringency, estimated to be
Tm
-5°C = (0.1x SSC at 65°C)(1x SSC = 0.15 mol/L NaCl,
0.0015 mol/L Na-citrate). Parallel hybridizations were
simultaneously performed using a 1.8-kb actin antisense probe. This was
used to assess RNA preservation and for normalization as a means to
judge overexpression (see below). The slides were then overlaid with
Kodak NTB-2 autoradiography emulsion, exposed for 2 weeks at 4°C,
developed photographically, and lightly stained with H&E.
All in situ hybridization results were evaluated independently (M. H. S.) without any knowledge of the parallel results of the multiple FISH or IHC analyses. Under the conditions of these experiments, a semiquantitative scale was developed and normalized to the level of actin expression in the adjacent section as follows: Neg/0 = <5 grains/cell, trace+ = 510 grains/cell, 1+ = 1015 grains/cell, 2+ = 1520 grains/cell, and 3+ = 2025 grains/cell. The typical breast biopsy had an actin signal of at least 1+. Cases with trace or negative actin were considered RNA degraded. Cases were considered to have strong overexpression of Her-2/neu if the level was two or more steps higher than the actin level on the same day/experiment. A one-step difference was graded as weak overexpression. Normal tissues within the sections typically had no overexpression and served as internal controls. Positive controls included an identically processed breast cancer cell line, BT-474, that has known eightfold amplification of Her-2/neu and a known high-grade ductal carcinoma that immunohistochemically was consistently 3+. These controls reproducibly were weak and strong Her-2/neu mRNA overexpressors, respectively. These controls were performed in each run, as were sense orientation controls to assess for background binding of probe.
Immunohistochemistry Using Monoclonal Antibody CB11
Unstained paraffin sections on electrostatically charged slides
were deparaffinized and rehydrated in three 1-minute changes each of
xylene, absolute alcohol, and 95% and 80% alcohol, and then placed in
1x PBS for 5 minutes. The modified labeled avidin biotin method was
used for detection. Cell conditioning was achieved through the use of
microwaving in citrate buffer for 15 minutes, followed by cooling of
the slides in the citrate solution at room temperature for 20 minutes.
The monoclonal antibody c-erb-B2 at manufacturers proprietary
concentration (Ventana) was dispensed onto the sections and allowed to
incubate for 1 hour at room temperature. Sections were then washed in
1x PBS, two changes of 3 minutes each, and biotinylated goat
anti-mouse IgG (Ventana) applied at a concentration of 15 µg/ml in
PBS containing 0.05 proclin 300 for 30 minutes. Two changes of 1x PBS
wash at room temperature were followed by the addition of
avidin-alkaline phosphatase (Ventana) at a concentration of 3000 µg/L
PBS with 0.05 proclin 300 for 30 minutes at room temperature. Sections
were then washed twice for 3 minutes each, in 1x PBS at room
temperature, and then the chromogen reaction product developed from
fast red K proprietary solution (Ventana), 10 minutes at room
temperature. Sections were then washed briefly in distilled water and
counterstained with hematoxylin for approximately 30 sections. After
dehydration in graded alcohols and xylene, coverslips were mounted with
Permount and examined by conventional optical microscopy.
Statistics
Statistical comparisons were made using Statview (SAS Institute,
Cary, NC).
| Results |
|---|
|
|
|---|
|
|
|
|
|
Comparison of Standard Immunohistochemistry Results and Oncoprotein
Detection by CODFISH
Five breast carcinomas and one positive cell line showed a strong
circumferential thick layer of cytoplasmic membrane staining with both
a monoclonal and polyclonal antibodies, and with the CB11 component of
CODFISH. Identical patterns and intensity of staining were noted.
However, HercepTest did also stain (grade 2 intensity) two cases
negative by all FISH methods, and by CB11 and the Zymed polyclonal
antibody sans epitope retrieval.
Gene Copy Enumeration by in Situ Hybridization
Three methods were used to determine copy number. A direct
two-color system, an indirect digoxigenin-labeled FISH system
(DigFISH) and the DigFISH component of CODFISH were used for this
purpose. There was excellent concordance among the three methods used
(Table 2)
. The presence of the intense fluorescent emission from fast red K did
not interfere with either capture or enumeration of the
digoxigenin-based gene enumeration by CODFISH.
|
| Discussion |
|---|
|
|
|---|
We chose Her-2/neu as a model system for first developing the assay in previously characterized cell lines, then extending the technique to a series of human inva-sive breast carcinomas for which gene copy number, mRNA expression, and Her-2/neu-encoded protein production were well established. The current controversy surrounding the accuracy of an immunohistochemistryassay for profiling this oncogenes overproduction as a means for screening women for serotherapy with a humanized monoclonal antibody highlights the potential benefits of an assay that simultaneously profiles both characteristics.3, 5, 8, 13
We were concerned that differences in cell conditioning and the use of
immunohistochemistry reagents might adversely effect the DNA in
situ hybridization portion of the assay. In fact correlations
between DigFISH and the digoxigenin-based: DNA in situ
hybridization component of CODFISH were excellent. The leveraging of
the fluorescent properties of fast red K may have numerous advantages
over other applications whereby FISH and labeling of specific
cellular populations may be of value. Figures 1
2
3
4
used confocal
microscopy; in clinical practice, the expense and time required for
confocal microscopy is not necessary, as gene copy counting is easily
performed by examining multiple nuclear focus planes.
We have also concluded that the CODFISH assay could be part of a cost-effective algorithm in the clinical approach to profiling gene amplification and oncoprotein overexpression. Concern has been expressed in the relevant literature regarding the clinical import of a 2+ versus a 3+ IHC result in the management of patients with breast carcinoma; a significant portion of such cases appear to be false-positive IHC results. The cardiotoxicity of Herceptin, alone or in combination with Adriamycin, itself a cardiotoxic drug, requires the greatest possible accuracy in selection of patients for Herceptin serotherapy. The CODFISH assay could be used in an algorithm whereby qualitative IHC assessment is done with brightfield mode, and any cases demonstrating borderline or equivocal results by immunohistochemistry could be very easily subjected to the balance of the CODFISH assay (DigFISH), correlating the ambiguous IHC results with definitive gene copy enumeration.
| Footnotes |
|---|
Accepted for publication February 18, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Tubbs, J. Pettay, M. Skacel, R. Powell, M. Stoler, P. Roche, and J. Hainfeld Gold-Facilitated in Situ Hybridization : A Bright-Field Autometallographic Alternative to Fluorescence in Situ Hybridization for Detection of HER-2/neu Gene Amplification Am. J. Pathol., May 1, 2002; 160(5): 1589 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
S A J Vaziri, R R Tubbs, G Darlington, and G Casey Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers Mol. Pathol., August 1, 2001; 54(4): 259 - 263. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |